Predicting the need for chemotherapy

Among women with early-stage breast cancer, the expression, or activity, of certain genes has been linked with the likelihood of cancer recurrence and chemotherapy benefit; testing tumor tissue for the expression of these genes can provide important information about prognosis and likely response to treatment. A genomic test that is included in guidelines from both the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN) is Oncotype DX®. Based on the expression of 21 genes, this test provides information about recurrence risk and likely chemotherapy benefit among women with newly diagnosed breast cancer that has not spread to the lymph nodes (node-negative) and is hormone receptor-positive. Oncotype DX has also shown promising results in women with node-positive breast cancer.[2]
For more information about OncotypeDX, visit http://www.mytreatmentdecision.com/